13F Holdings
中文EN

GRI GRI Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1824293 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY30.6%
TTM EPS YoY101.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-144.6%
ROA-107.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.8%
Debt / equity0.00x
Current ratio10.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.23x
Accruals ratio24.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue————$0
R&D expense$6.82M$3.77M$3.23M$242,000$5.19M
SG&A expense$5.16M$4.47M$8.15M$2.00M$4.07M
Operating income-$11.98M-$8.23M-$11.39M-$2.24M-$9.26M
Income tax$3,000$2,000———
Net income-$11.96M-$8.21M-$13.04M-$3.22M-$9.30M
EBITDA-$11.97M-$8.23M-$11.38M-$2.24M—
EPS (basic)-121.80-1,545.55-5,018.09-24.95-1.42
EPS (diluted)-121.80-1,545.55-5,018.09-24.95-1.42
Weighted avg. shares (diluted)98,1626,5472,598128,9946.54M
Balance sheet
Cash & equivalents$8.23M$5.03M$1.81M$9,000$90,000
Short-term investments———$0$3.81M
Current assets$8.59M$5.62M$2.93M$312,000$8.13M
PP&E, net$3,000$4,000$8,000$4,000$0
Total assets$8.67M$5.74M$2.96M$383,000$8.34M
Current liabilities$2.64M$1.64M$2.70M$1.99M$2.44M
Total liabilities$2.66M$1.71M$2.70M$2.01M$2.52M
Shareholders' equity$6.01M$4.03M$259,000-$1.62M-$4.85M
Shares outstanding497,69318,7682,909142,8206.81M
Cash flow statement
Operating cash flow-$10.19M-$8.61M-$8.99M-$1.08M-$8.31M
Capital expenditure$3,000$0$8,000$3,000$0
Free cash flow-$10.19M-$8.61M-$9.00M-$1.09M-$8.31M
Investing cash flow-$3,000$0-$8,000-$3,000-$3.84M
Financing cash flow$13.39M$11.83M$10.80M$1.01M$15.75M
Depreciation & amortization$4,000$4,000$4,000$3,000—
Stock-based compensation$793,000$148,000$388,000$25,000$626,000

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.